Search
Search
About
Log in
Join
Experiences with
Tecartus
Posts
Communities
5 public posts
Filter results
COVID: Staying Safe As The Virus Evolves - LLS Podcast / CLL Society’s COVID-19 Update December 5th, 2022 / Dec 15 2022 end Antibody Study
These include: • Bruton tyrosine kinase (BTK) inhibitors, such as Imbruvica® (ibrutinib), Brukinsa® (zanubrutinib) and Calquence® (acalabrutinib) • Anti-CD20 antibody treatments, such as Rituxan® (rituximab) and Gazyva® (obinutuzumab) • CD-19 targeting CAR T-therapy (Breyanzi®, Kymriah®,
Tecartus
™
These include: • Bruton tyrosine kinase (BTK) inhibitors, such as Imbruvica® (ibrutinib), Brukinsa® (zanubrutinib) and Calquence® (acalabrutinib) • Anti-CD20 antibody treatments, such as Rituxan® (rituximab) and Gazyva® (obinutuzumab) • CD-19 targeting CAR T-therapy (Breyanzi®, Kymriah®,
Tecartus
™
lankisterguy
Volunteer
in
CLL Support
2 years ago
COVID update: Who remains at higher risk? by LLS.org
These include: • Bruton tyrosine kinase (BTK) inhibitors, such as Imbruvica® (ibrutinib), Brukinsa® (zanubrutinib) and Calquence® (acalabrutinib) • Anti-CD20 antibody treatments, such as Rituxan® (rituximab) and Gazyva® (obinutuzumab) • CD-19 targeting CAR T-therapy (Breyanzi®, Kymriah®,
Tecartus
™
These include: • Bruton tyrosine kinase (BTK) inhibitors, such as Imbruvica® (ibrutinib), Brukinsa® (zanubrutinib) and Calquence® (acalabrutinib) • Anti-CD20 antibody treatments, such as Rituxan® (rituximab) and Gazyva® (obinutuzumab) • CD-19 targeting CAR T-therapy (Breyanzi®, Kymriah®,
Tecartus
™
lankisterguy
Volunteer
in
CLL Support
2 years ago
FDA Investigating 'Serious Risk' of Malignancy After CAR-T Therapy - Applies to all approved therapies, but benefits still outweigh risks
The notice and investigation pertain to all currently approved BCMA- and CD19-targeted CAR T-cell products:[/i] [i] Axicabtagene ciloleucel (Yescarta)[/i] [i] Brexucabtagene autoleucel (
Tecartus
)[/i] [i] Ciltacabtagene autoleucel (Carvykti)[/i] [i] Lisocabtagene maraleucel (Breyanzi)[
The notice and investigation pertain to all currently approved BCMA- and CD19-targeted CAR T-cell products:[/i] [i] Axicabtagene ciloleucel (Yescarta)[/i] [i] Brexucabtagene autoleucel (
Tecartus
)[/i] [i] Ciltacabtagene autoleucel (Carvykti)[/i] [i] Lisocabtagene maraleucel (Breyanzi)[
cujoe
in
CLL Support
7 months ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
LLS (Leukemia & Lymphoma Society) National Patient Registry Covid Vaccine guidelines
Patients who have had CAR T-therapy that targets the CD-19 protein (Breyanzi, Kymriah,
Tecartus
or Yescarta) should consider themselves immunosuppressed even if it has been more than two years from their treatment.
Patients who have had CAR T-therapy that targets the CD-19 protein (Breyanzi, Kymriah,
Tecartus
or Yescarta) should consider themselves immunosuppressed even if it has been more than two years from their treatment.
EPguy
in
MPN Voice
2 years ago
The LLS (USA) COVID-19 Vaccination Schedule - MODERATELY TO SEVERELY IMMUNOCOMPROMISED PATIENTS
Patients who have had CAR T-therapy that targets the CD-19 protein (Breyanzi, Kymriah,
Tecartus
or Yescarta) should consider themselves immunosuppressed even if it has been more than two years from their treatment.
Patients who have had CAR T-therapy that targets the CD-19 protein (Breyanzi, Kymriah,
Tecartus
or Yescarta) should consider themselves immunosuppressed even if it has been more than two years from their treatment.
lankisterguy
Volunteer
in
CLL Support
2 years ago
Filter results
Clear filters
Posted in
All communities
CLL Support
4 results
MPN Voice
1 result
Sort by
Most Relevant
Newest